Unique expression of 35 KDa protein in serum and cystic fluid of women with malignant ovarian cysts substantiates its role in disease progression

Badgwell, 2007, Early detection of ovarian cancer, Dis Markers, 23, 397, 10.1155/2007/309382 Jacobs, 2004, Progress and challenges in screening for early detection of ovarian cancer, Mol Cell Proteomics, 3, 355, 10.1074/mcp.R400006-MCP200 Greenlee, 2000, Cancer statistics, CA Cancer J Clin, 50, 7, 10.3322/canjclin.50.1.7 Goff, 2000, Ovarian carcinoma diagnosis, Cancer, 89, 2068, 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-Z Schildkraut, 1988, Familial ovarian cancer: a population-based case-control study, Am J Epidemiol, 128, 456, 10.1093/oxfordjournals.aje.a114994 Alam, 2001, Prevalence and management of ovarian tumors in Women and Children Hospital Abbottabad, J Ayub Med Coll Abbottabd, 13, 19 Aziz, 2003, Institution based tumor registry from Punjab: five year data based analysis, J Pak Med Assoc, 53, 350 Mansoor, 2015, Spectrum of ovarian tumors: histopathological study of 218 cases, Gulf J Oncol, 1, 64 Gupta, 2012, Fine needle aspiration cytology in ovarian lesions: an institutional experience of 584 cases, Cytopathology, 23, 300, 10.1111/j.1365-2303.2011.00896.x Daly, 2002, The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics, Cancer Cell, 1, 111, 10.1016/S1535-6108(02)00037-5 Mills, 2001, Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics, J Natl Cancer Inst (Bethesda), 93, 1437, 10.1093/jnci/93.19.1437 Bast, 1983, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N Engl J Med, 309, 883, 10.1056/NEJM198310133091503 Bandera, 2003, New technologies for the identification of markers for early detection of ovarian cancer, Curr Opin Obstet Gynecol, 15, 51, 10.1097/00001703-200302000-00008 Clarke, 2011, Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer, Gynecol Oncol, 122, 548, 10.1016/j.ygyno.2011.06.002 Topalak, 2002, Serum, pleural effusion and ascites CA-125 levels in ovarian cancer and non-ovarian benign and malignant diseases: a comparative study, Gynecol Oncoly, 85, 108, 10.1006/gyno.2001.6575 Kong, 2006, Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer, Gynecol Oncol, 100, 247, 10.1016/j.ygyno.2005.08.051 Ahmed, 2005, Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer, Proteomics, 5, 4625, 10.1002/pmic.200401321 An, 2006, Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer, J Proteome Res, 5, 1525, 10.1021/pr060010k Woolas, 1999, Ovarian cancer identified through screening with serum markers but not by pelvic imaging, Int J Gynecol Cancer, 9, 497, 10.1046/j.1525-1438.1999.99073.x Xu, 1998, Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers, JAMA, 280, 719, 10.1001/jama.280.8.719 Flyvbjerg, 1997, Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor, J Clin Endocrinol Metab, 82, 2308 Cohen, 1991, Insulin-like growth factors (IGFs), IGF receptors and IGF binding proteins in primary cultures of prostate epithelial cells, J Clin Endocrinol Metab, 73, 401, 10.1210/jcem-73-2-401 Kanety, 1993, Serum insulin-like growth factor binding protein 2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen, J Clin Endocrinol Metab, 77, 229 Hirano, 2004, Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers, Eur J Gynaecol Oncol, 25, 187 Katsaros, 2001, IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival, Eur J Cancer, 37, 478, 10.1016/S0959-8049(00)00423-8 Ott, 2003, Calgranulins in cystic fluid and serum from patients with ovarian carcinomas, Cancer Res, 63, 7507 Fu, 2005, A robust, streamlined, and reproducible method for proteomic analysis of serum by delipidation, albumin and IgG depletion, and two-dimensional gel electrophoresis, Proteomics, 5, 2656, 10.1002/pmic.200402048 Travis, 1973, Selective removal of albumin from plasma by affinity chromatography, Clin Chim Acta, 49, 49, 10.1016/0009-8981(73)90341-0 Maniwa, 2005, Studies on substantially increased proteins in follicular fluid of bovine ovarian follicular cysts using 2-D PAGE and MALDI-TOF MS, Reprod Biol Endocrinol, 3, 23, 10.1186/1477-7827-3-23 Agarwal, 1996, A mechanism for the suppression of estrogen production in polycystic ovary syndrome, J Clin Endocrinol Metab, 81, 3686 Van der Westhuizen, 1996, Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome, Ultrasound Obstet Gynecol, 7, 335, 10.1046/j.1469-0705.1996.07050335.x Rezepka-Gorska, 2004, FSH and LH serum/fluid ratios and malignant tumors of the ovary, Endocr Relat Cancer, 11, 315, 10.1677/erc.0.0110315 Bast, 1998, CA 125: the past and the future, Int J Biol Markers, 13, 179, 10.1177/172460089801300402 Zhang, 2004, Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer, Cancer Res, 64, 5882, 10.1158/0008-5472.CAN-04-0746 Mok, 2001, Prostasin, apotential serum marker for ovarian cancer: identification through microarraytechnology, J Natl Cancer Inst, 93, 1458, 10.1093/jnci/93.19.1458 Kim, 2002, Osteopontin as a potential diagnostic biomarker for ovarian cancer, JAMA, 287, 1671, 10.1001/jama.287.13.1671 Gercel-Taylor, 2004, Antibody response of cervical cancer patients to tumor cell antigens, p.1265 Mohamed, 2008, Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies, Electrophoresis, 29, 2645, 10.1002/elps.200700828 Hu, 2005, Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell culture derived from human ovarian cancer, Oncol Res, 15, 49, 10.3727/096504005775082101 Prokopenko, 2002, Identification and characterization of serum protein in patients with ovarian cancer, Bull Exp Biol Med, 133, 156, 10.1023/A:1015598805945 Holm, 1997, Folate receptors in malignant and benign tissues of human female genital tract, Biosci Rep, 17, 415, 10.1023/A:1027313502270 Korneeva, 2002, Cell-free 27 kDa heat shock protein (hsp27) and hsp27-cytochrome c complexes in the cervix of women with ovarian or endometrial cancer, Int J Cancer, 102, 483, 10.1002/ijc.10747 Jeschke, 2005, Development of monoclonal and polyclonal antibodies and ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumors, Anticancer Res, 25, 1581 Gagnon, 2008, Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients, Clin Cancer Res, 14, 764, 10.1158/1078-0432.CCR-07-0856 Reis, 2000, High concentrations of inhibin A and inhibin B in ovarian serous cystadenoma: relationship with oestradiol and nitric oxide metabolites, Mol Hum Reprod, 6, 1079, 10.1093/molehr/6.12.1079 Lindgren, 2002, The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors, Int J Oncol, 21, 583 Heinonen, 1991, Androgen production by epithelial ovarian tumors in post-menopausal women, Maturitas, 13, 117, 10.1016/0378-5122(91)90094-7 Ridgerheim, 1993, Steroid production in different parts of malignant and benign ovarian tumors, in vitro. Cancer Res, 53, 2309